| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
MMH1-NR targets the same non-covalent binding scaffold as MMH1 but lacks the reactive electrophilic warhead required for covalent engagement with DCAF16. As a negative control, it does not degrade BRD4, as it cannot form the covalent bond with Cys58 of DCAF16 that is essential for the degradation mechanism. The compound serves as a structurally matched control to differentiate between effects mediated by MMH1's target engagement and those arising from the covalent warhead or off-target effects.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that MMH1-NR functions as a negative control for the BRD4 degrader MMH1. Unlike MMH1, MMH1-NR contains a non-reactive ethyl group instead of the reactive acrylamide warhead and therefore does not degrade BRD4. This allows researchers to distinguish between specific BRD4 degradation effects and non-specific effects of the compound scaffold. Detailed in vitro activity data, including cellular degradation assays, are used to validate the specificity of MMH1-mediated BRD4 degradation.
|
| ln Vivo |
In vivo activity of MMH1-NR is not applicable in the traditional sense, as the compound is a negative control rather than a pharmacologically active agent. It is used in vivo to control for non-specific effects of the MMH1 scaffold in animal studies. Any in vivo effects observed with MMH1-NR would indicate off-target activities not related to BRD4 degradation. Detailed in vivo data for MMH1-NR are not extensively documented in the available literature.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for MMH1-NR is not applicable in the traditional sense, as the compound is a negative control rather than an enzyme inhibitor or receptor ligand. However, binding studies may be performed to confirm that MMH1-NR retains the non-covalent binding properties of MMH1 without covalent engagement. Surface plasmon resonance or isothermal titration calorimetry may be used to assess binding to target proteins. Standard protocols include MMH1 as a positive control for binding and degradation.
|
| Cell Assay |
In vitro cell-based assays for MMH1-NR are conducted using cell lines to evaluate its function as a negative control for BRD4 degradation. Cells are treated with MMH1-NR at various concentrations, and BRD4 protein levels are measured by Western blot to confirm that no degradation occurs. Cell viability and proliferation are assessed using MTT or CCK-8 assays to control for non-specific effects. Standard protocols include MMH1 as a positive control for BRD4 degradation and appropriate vehicle controls.
|
| Animal Protocol |
In vivo animal studies for MMH1-NR would typically be conducted alongside MMH1 to control for non-specific effects in mouse models. Animals would be administered MMH1-NR via appropriate routes, and BRD4 degradation in tissues would be confirmed by Western blot. Tumor growth, body weight, and clinical signs would be monitored. However, detailed in vivo protocols and efficacy data are not available from the search results. The compound is intended for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MMH1-NR include a molecular weight of 493.62 and a molecular formula of C26H31N5O3S. The compound appears as a white to light yellow solid. Solubility includes DMSO at 100 mg/mL (202.58 mM). Storage recommendations include powder at -20°C for 3 years or 4°C for 2 years, and in solvent at -80°C for 6 months or -20°C for 1 month. The compound is hygroscopic and requires careful handling.
|
| Toxicity/Toxicokinetics |
Toxicity information for MMH1-NR is limited. As a research-use negative control, standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results. The compound is a controlled substance and not for sale in certain territories.
|
| References | |
| Additional Infomation |
MMH1-NR is a negative control for the covalent molecular glue degrader MMH1, which is a DCAF16-based BRD4 degrader. MMH1-NR contains a non-reactive ethyl group instead of the reactive acrylamide warhead, preserving the complete non-covalent binding scaffold while eliminating DCAF16 Cys58 alkylation. It is used to distinguish specific BRD4 degradation effects from non-specific effects. It has a molecular weight of 493.62 and formula C26H31N5O3S.
|
| Molecular Formula |
C26H31N5O3S
|
|---|---|
| Molecular Weight |
493.62
|
| Appearance |
White to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~202.58 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0258 mL | 10.1292 mL | 20.2585 mL | |
| 5 mM | 0.4052 mL | 2.0258 mL | 4.0517 mL | |
| 10 mM | 0.2026 mL | 1.0129 mL | 2.0258 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
